Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis

被引：0
|
作者：
Krueger, J. G. [1 ]
Garcet, S. [1 ]
Cheng, J. [2 ]
Kumar, S. [3 ]
Tang, J. [3 ]
Blau, J. [2 ]
Zhao, Y. [2 ]
Zhang, W. [2 ]
Saha, B. [2 ]
Arunachalam, V. [3 ]
Heap, G. A. [2 ]
Thakker, P. [2 ]
Choudhury, A. [2 ]
机构：
[1] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA
[2] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, Cambridge, MA USA
[3] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, San Diego, CA USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2024年 / 144卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
265
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] MODULATION OF DISEASE-CENTRAL CYTOKINE PATHWAYS WITH TAK-279, A HIGHLY SELECTIVE ORAL TYK2 INHIBITOR, DEFINES CLINICAL RESPONSE IN PATIENTS WITH PSORIASIS
    Choudhury, Amit
    Garcet, Sandra
    Cheng, Jie
    Kumar, Sachin
    Tang, Jay
    Blau, Jessamyn
    Zhao, Yiwei
    Zhang, Wenwen
    Saha, Banishree
    Arunachalam, Vinu
    Heap, Graham A.
    Thakker, Paresh
    Krueger, James
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [2] Zasocitinib (TAK-279), an oral, allosteric, highly selective TYK2 inhibitor, modulates disease-central cytokine pathways that define clinical response in patients with moderate-to-severe plaque psoriasis
    Krueger, James G.
    Garcet, Sandra
    Cheng, Jie
    Kumar, Sachin
    Tang, Jay
    Blau, Jessamyn
    Zhang, Wenwen
    Saha, Banishree
    Arunachalam, Vinayagam
    Heap, Graham A.
    Winkelman, Warren
    Thakker, Paresh
    Choudhury, Amit
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [3] Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis
    Kong, K. F.
    Khan, M. A. W.
    Singh, N.
    Nguyen, V. A.
    Wilson, E.
    Tang, J.
    Marusic, S.
    Xia, G.
    Petrakis, I.
    Nguyen, D. G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I437 - I438
  • [4] EFFICACY OF THE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR TAK-279 IN TWO PRECLINICAL MOUSE MODELS OF COLITIS
    Kong, Kok-Fai
    Khan, Md A. Wadud
    Singh, Namita
    Van Anh Nguyen
    Wilson, Elizabeth
    Tang, Jay
    Marusic, Suzana
    Xia, Guliang
    Petrakis, Ioannis
    Nguyen, Deborah G.
    GASTROENTEROLOGY, 2024, 166 (05) : S1399 - S1399
  • [5] Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279
    Leit, Silvana
    Greenwood, Jeremy
    Carriero, Samantha
    Mondal, Sayan
    Abel, Robert
    Ashwell, Mark
    Blanchette, Heather
    Boyles, Nicholas A. A.
    Cartwright, Mark
    Collis, Alan
    Feng, Shulu
    Ghanakota, Phani
    Harriman, Geraldine C. C.
    Hosagrahara, Vinayak
    Kaila, Neelu
    Kapeller, Rosanna
    Rafi, Salma B. B.
    Romero, Donna L. L.
    Tarantino, Paul M. M.
    Timaniya, Jignesh
    Toms, Angela V. V.
    Wester, Ronald T. T.
    Westlin, William
    Srivastava, Bhaskar
    Miao, Wenyan
    Tummino, Peter
    McElwee, Joshua J. J.
    Edmondson, Scott D. D.
    Masse, Craig E. E.
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (15) : 10473 - 10496
  • [6] TAK-279, A SELECTIVE ORAL TYK2 INHIBITOR, REDUCES BSA INVOLVEMENT IN A PHASE 2B TRIAL IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Laquer, Vivian
    Kircik, Leon
    Sadick, Neil
    Weisman, Jamie
    Zhao, Yi- wei
    Blau, Jessamyn
    Zhang, Wenwen
    Uy, Jonathan
    Winkelman, Warren
    Gooderham, Melinda
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [7] ABSOLUTE PASI REDUCTIONS IN A PHASE 2B TRIAL OF THE SELECTIVE ORAL TYK2 INHIBITOR, TAK-279, IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Green, Lawrence
    Ferris, Laura
    Moore, Angela
    Zirwas, Matthew
    Zhao, Yiwei
    Blau, Jessamyn
    Zhang, Wenwen
    Uy, Jonathan
    Winkelman, Warren
    Vender, Ronald
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [8] Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial
    Armstrong, April W.
    Gooderham, Melinda
    Lynde, Charles
    Maari, Catherine
    Forman, Seth
    Green, Lawrence
    Laquer, Vivian
    Zhang, Xinyan
    Franchimont, Nathalie
    Gangolli, Esha A.
    Blau, Jessamyn
    Zhao, Yiwei
    Zhang, Wenwen
    Srivastava, Bhaskar
    Heap, Graham
    Papp, Kim
    JAMA DERMATOLOGY, 2024, 160 (10) : 1066 - 1074
  • [9] Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
    Kavanaugh, Arthur
    Muensterman, Elena
    Lertratanakul, Apinya
    Hong, Ting
    Chen, Jingjing
    Pothula, Peter
    Mark, Ejim
    Kivitz, Alan
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4770 - 4772
  • [10] Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
    Gottlieb, Alice
    Muensterman, Elena
    Kivitz, Alan
    Dokoupilova, Eva
    Lertratanakul, Apinya
    Hong, Ting
    Chen, Jingjing
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 3007 - 3011
12345